Media headlines about Novan (NASDAQ:NOVN) have been trending somewhat negative recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novan earned a media sentiment score of -0.07 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 42.8279855800906 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:

NOVN has been the topic of several research analyst reports. ValuEngine raised shares of Novan from a “strong sell” rating to a “sell” rating in a research note on Friday, September 15th. Zacks Investment Research raised shares of Novan from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, Wedbush reaffirmed a “neutral” rating and set a $6.00 price objective on shares of Novan in a research note on Monday, September 25th.

Novan (NASDAQ:NOVN) traded up $0.14 on Friday, hitting $4.50. 64,700 shares of the stock traded hands, compared to its average volume of 215,259. Novan has a twelve month low of $3.52 and a twelve month high of $28.82.

COPYRIGHT VIOLATION WARNING: “Somewhat Negative Press Coverage Somewhat Unlikely to Impact Novan (NOVN) Stock Price” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.watchlistnews.com/somewhat-negative-press-coverage-somewhat-unlikely-to-impact-novan-novn-stock-price/1765666.html.

Novan Company Profile

Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).

Insider Buying and Selling by Quarter for Novan (NASDAQ:NOVN)

Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with Analyst Ratings Network's FREE daily email newsletter.